These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17635951)

  • 1. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.
    Brohet RM; Goldgar DE; Easton DF; Antoniou AC; Andrieu N; Chang-Claude J; Peock S; Eeles RA; Cook M; Chu C; Noguès C; Lasset C; Berthet P; Meijers-Heijboer H; Gerdes AM; Olsson H; Caldes T; van Leeuwen FE; Rookus MA
    J Clin Oncol; 2007 Sep; 25(25):3831-6. PubMed ID: 17635951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group.
    Andrieu N; Easton DF; Chang-Claude J; Rookus MA; Brohet R; Cardis E; Antoniou AC; Wagner T; Simard J; Evans G; Peock S; Fricker JP; Nogues C; Van't Veer L; Van Leeuwen FE; Goldgar DE
    J Clin Oncol; 2006 Jul; 24(21):3361-6. PubMed ID: 16801631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Narod SA; Dubé MP; Klijn J; Lubinski J; Lynch HT; Ghadirian P; Provencher D; Heimdal K; Moller P; Robson M; Offit K; Isaacs C; Weber B; Friedman E; Gershoni-Baruch R; Rennert G; Pasini B; Wagner T; Daly M; Garber JE; Neuhausen SL; Ainsworth P; Olsson H; Evans G; Osborne M; Couch F; Foulkes WD; Warner E; Kim-Sing C; Olopade O; Tung N; Saal HM; Weitzel J; Merajver S; Gauthier-Villars M; Jernstrom H; Sun P; Brunet JS
    J Natl Cancer Inst; 2002 Dec; 94(23):1773-9. PubMed ID: 12464649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS).
    Andrieu N; Goldgar DE; Easton DF; Rookus M; Brohet R; Antoniou AC; Peock S; Evans G; Eccles D; Douglas F; Noguès C; Gauthier-Villars M; Chompret A; Van Leeuwen FE; Kluijt I; Benitez J; Arver B; Olah E; Chang-Claude J; ; ; ;
    J Natl Cancer Inst; 2006 Apr; 98(8):535-44. PubMed ID: 16622123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.
    Haile RW; Thomas DC; McGuire V; Felberg A; John EM; Milne RL; Hopper JL; Jenkins MA; Levine AJ; Daly MM; Buys SS; Senie RT; Andrulis IL; Knight JA; Godwin AK; Southey M; McCredie MR; Giles GG; Andrews L; Tucker K; Miron A; Apicella C; Tesoriero A; Bane A; Pike MC; ; ; Whittemore AS
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1863-70. PubMed ID: 17021353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.
    Schrijver LH; Antoniou AC; Olsson H; Mooij TM; Roos-Blom MJ; Azarang L; Adlard J; Ahmed M; Barrowdale D; Davidson R; Donaldson A; Eeles R; Evans DG; Frost D; Henderson A; Izatt L; Ong KR; Bonadona V; Coupier I; Faivre L; Fricker JP; Gesta P; van Engelen K; Jager A; Menko FH; Mourits MJE; Singer CF; Tan YY; Foretova L; Navratilova M; Schmutzler RK; Ellberg C; Gerdes AM; Caldes T; Simard J; Olah E; Jakubowska A; Rantala J; Osorio A; Hopper JL; Phillips KA; Milne RL; Beth Terry M; Noguès C; Engel C; Kast K; Goldgar DE; van Leeuwen FE; Easton DF; Andrieu N; Rookus MA;
    Am J Obstet Gynecol; 2021 Jul; 225(1):51.e1-51.e17. PubMed ID: 33493488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.
    Milne RL; Knight JA; John EM; Dite GS; Balbuena R; Ziogas A; Andrulis IL; West DW; Li FP; Southey MC; Giles GG; McCredie MR; Hopper JL; Whittemore AS
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):350-6. PubMed ID: 15734957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.
    Figueiredo JC; Haile RW; Bernstein L; Malone KE; Largent J; Langholz B; Lynch CF; Bertelsen L; Capanu M; Concannon P; Borg A; Børresen-Dale AL; Diep A; Teraoka S; Torngren T; Xue S; Bernstein JL
    Breast Cancer Res Treat; 2010 Feb; 120(1):175-83. PubMed ID: 19597986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO).
    Lecarpentier J; Noguès C; Mouret-Fourme E; Gauthier-Villars M; Lasset C; Fricker JP; Caron O; Stoppa-Lyonnet D; Berthet P; Faivre L; Bonadona V; Buecher B; Coupier I; Gladieff L; Gesta P; Eisinger F; Frénay M; Luporsi E; Lortholary A; Colas C; Dugast C; Longy M; Pujol P; Tinat J; ; Lidereau R; Andrieu N
    Breast Cancer Res; 2012 Jul; 14(4):R99. PubMed ID: 22762150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
    Kuchenbaecker KB; Hopper JL; Barnes DR; Phillips KA; Mooij TM; Roos-Blom MJ; Jervis S; van Leeuwen FE; Milne RL; Andrieu N; Goldgar DE; Terry MB; Rookus MA; Easton DF; Antoniou AC; ; McGuffog L; Evans DG; Barrowdale D; Frost D; Adlard J; Ong KR; Izatt L; Tischkowitz M; Eeles R; Davidson R; Hodgson S; Ellis S; Nogues C; Lasset C; Stoppa-Lyonnet D; Fricker JP; Faivre L; Berthet P; Hooning MJ; van der Kolk LE; Kets CM; Adank MA; John EM; Chung WK; Andrulis IL; Southey M; Daly MB; Buys SS; Osorio A; Engel C; Kast K; Schmutzler RK; Caldes T; Jakubowska A; Simard J; Friedlander ML; McLachlan SA; Machackova E; Foretova L; Tan YY; Singer CF; Olah E; Gerdes AM; Arver B; Olsson H
    JAMA; 2017 Jun; 317(23):2402-2416. PubMed ID: 28632866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
    Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
    Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
    Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
    Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
    J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
    Cullinane CA; Lubinski J; Neuhausen SL; Ghadirian P; Lynch HT; Isaacs C; Weber B; Moller P; Offit K; Kim-Sing C; Friedman E; Randall S; Pasini B; Ainsworth P; Gershoni-Baruch R; Foulkes WD; Klijn J; Tung N; Rennert G; Olopade O; Couch F; Wagner T; Olsson H; Sun P; Weitzel JN; Narod SA
    Int J Cancer; 2005 Dec; 117(6):988-91. PubMed ID: 15986445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
    Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
    Phillips KA; Milne RL; Rookus MA; Daly MB; Antoniou AC; Peock S; Frost D; Easton DF; Ellis S; Friedlander ML; Buys SS; Andrieu N; Noguès C; Stoppa-Lyonnet D; Bonadona V; Pujol P; McLachlan SA; John EM; Hooning MJ; Seynaeve C; Tollenaar RA; Goldgar DE; Terry MB; Caldes T; Weideman PC; Andrulis IL; Singer CF; Birch K; Simard J; Southey MC; Olsson HL; Jakubowska A; Olah E; Gerdes AM; Foretova L; Hopper JL
    J Clin Oncol; 2013 Sep; 31(25):3091-9. PubMed ID: 23918944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.
    Runnebaum IB; Wang-Gohrke S; Vesprini D; Kreienberg R; Lynch H; Moslehi R; Ghadirian P; Weber B; Godwin AK; Risch H; Garber J; Lerman C; Olopade OI; Foulkes WD; Karlan B; Warner E; Rosen B; Rebbeck T; Tonin P; Dubé MP; Kieback DG; Narod SA
    Pharmacogenetics; 2001 Oct; 11(7):635-8. PubMed ID: 11668223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update.
    Ginsburg O; Ghadirian P; Lubinski J; Cybulski C; Lynch H; Neuhausen S; Kim-Sing C; Robson M; Domchek S; Isaacs C; Klijn J; Armel S; Foulkes WD; Tung N; Moller P; Sun P; Narod SA;
    Breast Cancer Res Treat; 2009 Mar; 114(1):127-35. PubMed ID: 18483851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for
    Li H; Terry MB; Antoniou AC; Phillips KA; Kast K; Mooij TM; Engel C; Noguès C; Stoppa-Lyonnet D; Lasset C; Berthet P; Mari V; Caron O; ; Barrowdale D; Frost D; Brewer C; Evans DG; Izatt L; Side L; Walker L; Tischkowitz M; Rogers MT; Porteous ME; Snape K; ; Meijers-Heijboer HEJ; Gille JJP; Blok MJ; Hoogerbrugge N; ; Daly MB; Andrulis IL; Buys SS; John EM; McLachlan SA; Friedlander M; ; Tan YY; Osorio A; Caldes T; Jakubowska A; Simard J; Singer CF; Olah E; Navratilova M; Foretova L; Gerdes AM; Roos-Blom MJ; Arver B; Olsson H; Schmutzler RK; Hopper JL; Milne RL; Easton DF; Van Leeuwen FE; Rookus MA; Andrieu N; Goldgar DE
    Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):368-378. PubMed ID: 31792088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.